Entry Point Capital, LLC Akero Therapeutics, Inc. Call Options Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding AKRO
# of Institutions
172Shares Held
72.7MCall Options Held
178KPut Options Held
164K-
Janus Henderson Group PLC London, X06.88MShares$243 Million0.09% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$197 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$192 Million2.13% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$185 Million3.88% of portfolio
-
Wellington Management Group LLP Boston, MA5.11MShares$180 Million0.02% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $1.64B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...